新的数据显示,Crinetics的药物PALSONIFY表明,从长远来看,治疗这种药物非常有效。 Crinetics' drug PALSONIFY shows long-term effectiveness in treating acromegaly, new data reveals.

Crinetics制药公司将在ENDO 2025上提供新数据,表明其调查性药物PALSONIFY(paltusotine)长期有效控制大麻毒。 Crinetics Pharmaceuticals will present new data at ENDO 2025, showing that its investigational drug PALSONIFY (paltusotine) effectively controls acromegaly over the long term. 该药物保持了稳定的IGF-1水平,降低了症状严重性,并获得良好治疗。 The drug maintains stable IGF-1 levels, reduces symptom severity, and is well-tolerated. 来自PATH FNDR-1和PATH FNDR-2试验的数据表明,病人的症状持续改善,安全情况也始终如一。 Data from the PATHFNDR-1 and PATHFNDR-2 trials indicate sustained improvements in patient symptoms and a consistent safety profile.